Chinese Journal of Integrative Medicine最新文献

{"title":"Maxing Shigan Decoction Regulates Immune Inflammatory Response of Adenovirus Pneumonia by Inhibiting cGAS-STING Pathway.","authors":"Si-Wei Wang, Cheng Peng, Li Deng, Guo-Qian Cong, Feng Yan, Jun-Fu Na, Li-Jian Pang","doi":"10.1007/s11655-026-3959-5","DOIUrl":"https://doi.org/10.1007/s11655-026-3959-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate whether Maxing Shigan Decoction (MSD) regulates the immune-inflammatory response of adenovirus pneumonia (AVP) by inhibiting the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway.</p><p><strong>Methods: </strong>A mouse model of AVP was induced by intranasal instillation of human adenovirus type 3 (Ad3), and Raw264.7 cells were infected with Ad3 to establish an in vitro model. The in vivo and in vitro experiments both included 6 groups: control, model, ribavirin (RIB), and low- (MSD-L), medium- (MSD-M), and high-dose MSD (MSD-H) groups. Moreover, the cGAS-STING pathway agonist SR-717 was used during the cell experiment. Hematoxylin and eosin (HE) staining was conducted to identify pathological changes in the lung tissue of AVP mice. The quantity of CD3⁺CD8⁺ T cells in the mouse lung tissue was evaluated using flow cytometry. The expression levels of cGAS, STING, interferon-β (IFN-β), TANK binding kinase 1 (TBK1), and interferon regulatory factor 3 (IRF3) were assessed by Western blot for protein levels and quantitative polymerase chain reaction for mRNA levels.</p><p><strong>Results: </strong>In vivo, MSD and RIB significantly reduced lung tissue inflammation in the AVP mouse model, and reduced the excessive immune response mediated by CD3⁺CD8⁺ T cells (P<0.01). The cGAS, STING, IFN-β, TBK1, and IRF3 protein and mRNA levels were markedly elevated in model mice (P<0.01), while treatment with MSD and RIB significantly reduced these levels (P<0.01). In vitro experiments showed the similar results of levels of cGAS, STING, IRF3, TBK1, and IFN-β proteins and mRNAs. However, these levels significantly decreased with MSD and RIB treatment were restored after treatment with SR-717 (P<0.01).</p><p><strong>Conclusions: </strong>MSD modulated the immune inflammatory response in AVP by inhibiting the cGAS-STING pathway. It protected lung tissue from damage caused by excessive immune responses and inflammatory reactions.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Acupuncture Combined with Hydroxychloroquine in Treating Primary Sjögren's Syndrome: A Randomized Controlled Trial.","authors":"Jian-Bin Li, Hang Lu, Yi-Hua Fan, Wei Liu","doi":"10.1007/s11655-026-4253-2","DOIUrl":"https://doi.org/10.1007/s11655-026-4253-2","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of acupuncture combined with hydroxychloroquine (HCQ) in patients with primary Sjögren's syndrome (pSS) and to explore the underlying mechanisms of acupuncture effect.</p><p><strong>Methods: </strong>This study was designed as a randomized controlled trial (RCT) and included 138 pSS patients who were equally and randomly assigned to the treatment group or the sham acupuncture control group (69 cases in each group). The control group received HCQ sulfate tablets (0.2 g, twice daily) combined with sham acupuncture, whereas the treatment group received real acupuncture in addition to HCQ treatment. Acupuncture at Baihui (GV 20), Zusanli (ST 36), Sanyinjiao (SP 6), Taixi (KI 3), etc. was administered. Both groups underwent 8 treatment courses, with a 4-week follow-up. The primary efficacy endpoint was the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) score. The secondary endpoints included clinical symptom scores, laboratory indicators, and scores for anxiety (Hospital Anxiety and Depression Scale-anxiety, HADS-A) and depression (HADS-D). Safety assessments including vital signs monitoring and laboratory tests were conducted at weeks 0, 2, 4, 6, and 8, and adverse events were evaluated throughout the study.</p><p><strong>Results: </strong>A total of 57 patients in the treatment group and 62 in the control group completed the full course of treatment. After treatment, both groups presented a reduction in ESSPRI scores, eye dryness numerical rating scale (NRS), mouth dryness NRS, and EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scores compared with the baseline values and an increase in the salivary flow rate, Schirmer test results, and tear film break-up time (BUT) scores compared with the baseline values (P<0.05). The erythrocyte sedimentation rate (ESR), IgG, and IgA level were significantly lower than those at baseline (all P<0.05). Compared with the control group, the treatment group had significantly lower ESSPRI scores, eye dryness NRS, and mouth dryness NRS and significantly higher salivary flow rates, Schirmer test results, and BUT scores (all P<0.05), as well as lower HADS-A scores (P<0.001); both groups had a statistically significant difference in FAS analysis of HADS-D scores (P=0.020), and the difference was more significant in PPS analysis (P=0.003), with significant improvement within the treatment group (P=0.012). The incidence of adverse events was not significantly different between the two groups (P>0.05).</p><p><strong>Conclusions: </strong>Acupuncture combined with HCQ treatment is more effective than HCQ alone in improving dry mouth and dry eye symptoms in pSS patients, with a good safety profile. Additionally, acupuncture treatment may indirectly alleviate anxiety and depression symptoms by improving clinical outcomes such as dry mouth and dry eye. (Registration No. TCTR20230116003).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Plant-Derived Natural Products: An In-depth Review of Compounds and Potential Applications in Skin Aging.","authors":"Zhen-Zhen Zhao, Fu-Gui Liu, Li-Juan Zhu, Li Li, Lan Jiang","doi":"10.1007/s11655-026-4251-4","DOIUrl":"https://doi.org/10.1007/s11655-026-4251-4","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2026-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Berberine on Improving Reproduction Disorder in Female Mice with Type 2 Diabetes Mellitus.","authors":"Zhi Wang, Shen Chen, Hong-Zhan Wang, Yang Gao, Xin-Yue Jiang, Jing-Yuan Lu, Wei-Long Zhang, Zi-Rui Zhao, Hao Su, Ke-Xin Nie, Hui Dong, Xiao-Hu Xu","doi":"10.1007/s11655-026-4247-0","DOIUrl":"10.1007/s11655-026-4247-0","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of berberine (BBR) and elucidate its underlying mechanisms through both in vivo and in vitro models of reproductive dysfunction associated with type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>In vivo, after acclimation, db/db mice (n=32) were randomized into model, low-dose BBR, high-dose BBR, and metformin groups of 8 in each, while BKS mice served as controls (n=8). Mice received daily gavage for 6 weeks (BBR: 150 or 300 mg/kg per day; metformin: 100 mg/kg per day; vehicle for controls). Ovarian and uterine morphology were assessed by HE staining, including follicle classification/counting and endometrial thickness measurement. Systemic metabolism was evaluated by oral glucose tolerance test and serum lipid profiling, including total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low density lipoprotein cholesterol. Serum metabolomics was performed using LC-MS to measure hormonal level. Ovarian and uterine transcriptomes were profiled by RNA sequencing; differentially expressed genes were identified and subjected to GO/KEGG enrichment and PPI network analysis. Key targets, including aquaporin (Aqp), 3, 5 and 7, were validated by qPCR and immunohistochemistry. In vitro, KGN cells were exposed to high glucose (30 mmol/L) and treated with BBR (10 or 25 µ mol/L) or metformin (12.5 or 25 mmol/L). CCK-8, immunofluorescence, TUNEL staining, and Western blotting (apoptosis markers and cAMP-PKA pathway proteins) were used to evaluate cellular phenotypes and signaling changes.</p><p><strong>Results: </strong>High-dose BBR improved follicle development, restored glycolipid metabolism, and balanced hormonal levels, particularly dehydroepiandrosterone sulfate (P<0.05). It modulated the expressions of Crhr1 and Adrb2 in granulosa cells, alleviatied apoptosis through the cAMP-PKA signaling pathway (P<0.05). BBR also enhanced Bcl2 expression while reducing Bax and Caspase-3 levels (P<0.05). Furthermore, it restored endometrial thickness and the expressions of Aqp3, Aqp5, and Aqp7 (P<0.05).</p><p><strong>Conclusions: </strong>BBR effectively improves ovarian function and endometrial receptivity in T2DM by regulating the cAMP-PKA pathway and apoptosis. These findings highlight its potential as a therapeutic agent for reproductive dysfunction in women with T2DM.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"884-893"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148788901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oxidative Stress in Ovarian Aging and Progress in Chinese Medicine Therapy.","authors":"Jie Ren, Ying Yan, Jing Ma, Lin-Ling Wu, Xiu-Ting Mo","doi":"10.1007/s11655-026-4239-0","DOIUrl":"10.1007/s11655-026-4239-0","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"951-959"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148763069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-pharmaceutical Chinese Medical Therapies for Nausea and Vomiting of Pregnancy: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials.","authors":"Yi-Xuan Xie, Ya-Nan Sun, Chang-He Yu","doi":"10.1007/s11655-026-4243-4","DOIUrl":"10.1007/s11655-026-4243-4","url":null,"abstract":"<p><strong>Background: </strong>Nausea and vomiting of pregnancy (NVP) are common symptoms during early pregnancy that significantly impact maternal quality of life and fetal development. Given concerns about the safety of pharmacological treatments, non-pharmaceutical Chinese medical therapies (NPCT) have been new topics of great interest due to their minimal side effects.</p><p><strong>Objective: </strong>To evaluate the efficacy and safety of NPCT for the management of NVP through an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.</p><p><strong>Methods: </strong>Eligible data were retrieved from online databases up to August 31, 2024 for subsequent analyses. The quality of included reviews and the certainty of evidence were evaluated using the AMSTAR-2 tool and the GRADE criteria, respectively. Subgroup analyses were performed based on intervention types, treatment methods, and control conditions to explore potential sources of heterogeneity. Primary outcomes included the severity of NVP, treatment effectiveness, and safety.</p><p><strong>Results: </strong>This study included a total of 22 systematic reviews or meta-analyses on various NPCT interventions. The AMSTAR-2 assessment rated 6 studies as high quality, 2 as moderate, and 14 as low or very low quality. The GRADE evaluation categorized evidence as moderate for 5 comparisons, low for 15, and very low for 5 out of the 25 outcome measures. Further analyses revealed the superior effects of acupuncture in decreasing the Pregnancy-Unique Quantification of Emesis score (MD, -1.32; 95% CI, -1.69 to -0.95; moderate evidence), increasing the rate of negative urinary ketone bodies (RR, 1.32; 95% CI, 1.14 to 1.53; moderate evidence); as well as reducing anxiety (MD, 0.78; 95% CI, -1.13 to 2.6; moderate evidence) and depression scores (MD, 0.20; 95% CI, -2.05 to 2.46; moderate evidence).</p><p><strong>Conclusions: </strong>NPCT, particularly acupuncture, may have potential benefits in alleviating NVP. However, due to limited overall quality and certainty of evidence, studies with more rigorous designs and larger sample sizes should be included to produce higher-quality evidence, thereby better informing clinical practice. (PROSPERO registration No. CRD42024590714).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"919-925"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"System Pharmacology-Based Anti-proliferation and Anti-angiogenesis Mechanisms of Oridonin in Psoriasis Keratinocytes by Blocking PI3K/AKT Signaling Pathway.","authors":"Yang Yang, Su-Wei Tang, Xin-Xin Wu, Wen-Cheng Jiang, Qi-Long Chen","doi":"10.1007/s11655-026-4242-5","DOIUrl":"10.1007/s11655-026-4242-5","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To study the anti-proliferative and anti-angiogenic mechanism of oridonin in psoriatic keratinocytes by blocking phosphatidylinositol 3-kinase (PI3K/Akt) signaling pathway based on system pharmacology.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Protein targets of oridonin and psoriasis-related genes were predicted and their overlap was determined using the Venny package in R. The DAVID database was used for enrichment analysis. The oridonin-psoriasis-target and oridonin-target-pathway (OTP) networks associated with psoriasis, as well as a protein-protein interaction, were constructed using Cytoscape. Molecular docking with AutoDock was used to verify the relationships between oridonin and core targets, and ZDOCK was used to assess interactions between core proteins. All bioinformatics results were verified empirically. The mRNA levels of core targets in oridonin-treated cells were measured using real-time q-PCR. The HaCaT keratinocytes were divided to 4 groups: control, low-, medium- and high-concentration groups and treated with different concentrations of oridonin (1, 5 and 10 µmol/L) for 18 h, and then stimulated with tumor necrosis factor (TNF)-α (20 ng/mL) for 6 h. Western blot was used to detect PI3K/Akt pathway protein levels.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Seventy-three targets were found to be strongly associated with the effects of oridonin on psoriasis. The Cluster ONE algorithm was used to extract 6 kernel clusters from the PPI network, and 9 PPI interaction pairs comprising 13 targets showed combined scores ⩾0.999. The OTP network, molecular docking, and protein interaction simulations indicated that oridonin targeted Sirtuin 1 (SIRT1), cyclin dependent kinase 2 (CDK2), Src tyrosine protein kinase (SRC), proteintyrosine phosphatase, nonreceptor-type (PTPN), and SIRT1-tumor protein p53 (TP53), with the CDK2-TP53, SRC-heat shock protein 90 alpha family class a member 1 (HSP90AA1), and PTPN1-epidermal growth factor receptor (EGFR) interaction pairs regulating the PI3K-Akt signaling pathway. Oridonin was observed to block hyperplasia in HaCaT keratinocytes, accompanied by reduced levels of TNF-α, interleukin (IL-)-6, and IL-1 β (P&lt;0.05 or P&lt;0.01). qPCR measurements showed that oridonin significantly inhibited the expression of angiogenesis-related genes, including C-X-C chemokine receptor type 7, C-X-C motif chemokine ligand 12, and vascular endothelial growth factor (P&lt;0.05 or P&lt;0.01). In addition, the qPCR results showed significant changes in the mRNA levels of SIRT1, CDK2, SRC, PTPN1, TP53, HSP90AA1, and EGFR, and Western blot indicated marked changes in the protein levels of cleaved caspase-3, BAD, Bcl-2, p-ERK1/2, and p-p38 after oridonin treatment (P&lt;0.05 or P&lt;0.01).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The study identified the primary oridonin targets during psoriasis treatment using network pharmacology. Bioinformatics analysis with empirical verification demonstrated strong associations between SIRT1, CDK2, ","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"903-910"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147763946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated Network Pharmacology and Proteomics Reveal Anti-tumor Mechanism of Securinine in Ovarian Cancer.","authors":"Xin-Min Tu, Ya-Juan Zhang, Cheng-Yu Miao, Jie Kang, Yu-Heng Shi, Chen-Lin Wang, Bing Han, Guo-Yin Kai","doi":"10.1007/s11655-026-4246-1","DOIUrl":"10.1007/s11655-026-4246-1","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect and underlying mechanism of securinine (Sec) in ovarian cancer (OC) based on network pharmacology, in vivo experiments and proteomics.</p><p><strong>Methods: </strong>ES2 cells were treated with different concentrations of Sec (6.25, 12.5, 25, 50, and 100 µmol/L) for 24 h. The cell viability was determined using the MTT assay. ES2 xenograft nude mice were randomly divided into 4 groups (5 mice per group): tumor control, positive control carboplatin (12.5 mg/kg), low-dose of Sec (10 mg/kg), and high-dose of Sec (20 mg/kg). During the treatment period, body weight and tumor volume were monitored. Major organs and tumor tissues were collected for organ index calculation and HE staining. The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatinine were measured using commercial kits. Network pharmacology was used to predict the targets of Sec in OC. The proteomics analysis of tumor tissues was employed to identify key pathways regulated by Sec. The mRNA and protein levels of epidermal growth factor receptor (EGFR), hypoxia-inducible factor alpha (HIF-α), matrix metalloproteinase-9 (MMP9), mechanistic target of rapamycin (mTOR), nuclear factor kappa-B (NF-κB), signal transducer and activator of transcription 3 (STAT3), and the key targets in peroxisome proliferator-activated receptor (PPAR) signaling pathway were determined by qRT-PCR and Western blot, respectively. Molecular docking was used to analyze the interactions between Sec and the core targets.</p><p><strong>Results: </strong>Sec (6.25-100 µmol/L) inhibited ES2 cell proliferation (P<0.05 or P<0.01). Sec inhibited tumor growth in ES2 xenograft nude mice without toxicity in heart, liver, spleen, lung, and kidneys (P<0.05 or P<0.01). Network pharmacology identified 6 core targets associated with Sec's activity: EGFR, HIF-α, MMP9, mTOR, NF-κB, and STAT3. Proteomics analysis revealed PPAR signaling pathway as a key role. qRT-PCR confirmed that Sec significantly inhibited the mRNA levels of mTOR, NF-κB, STAT3, fatty acid-binding protein 3 (FABP3), FABP4, peroxisome proliferator-activated receptor alpha (PPAR-α), and PPAR-δ (P<0.05 or P<0.01). Western blot analysis demonstrated that Sec markedly suppressed the expression of FABP3, STAT3, and NF-κB (P<0.05 or P<0.01). Molecular docking revealed high binding affinity between Sec and FABP3, FABP4, mTOR, and NF-κB.</p><p><strong>Conclusion: </strong>Sec inhibits OC cell proliferation and tumor growth through the NF-κB and PPAR signaling pathways.</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"894-902"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148444586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qushi Juanbi Granules Combined with Shenling Baizhu Powder in Rheumatoid Arthritis Patients with Low Disease Activity and Pi Deficiency and Dampness Pattern: A Randomized, Double-Blind, Controlled Trial.","authors":"Yi-Hong Yang, Kai-Xin Gao, You-Bang Liang, Yu Wen, Yi-Hang Yu, Sheng-Qin Yang, Chuan-Jian Lu, Mao-Jie Wang, Xiu-Min Chen, Run-Yue Huang","doi":"10.1007/s11655-026-4221-x","DOIUrl":"10.1007/s11655-026-4221-x","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of Qushi Juanbi Granules (QSJB) combined with Shenling Baizhu Powder (SLBZ) for treating rheumatoid arthritis (RA) patients with low disease activity (LDA) and Pi (Spleen) deficiency and dampness dampness pattern.</p><p><strong>Methods: </strong>This is a single-centre, randomized, double-blind, placebo-controlled clinical trial executed from November 29, 2022 to August 15, 2024. Participants were randomly assigned to the QSJB (with placebo) group or the QSJB+SLBZ group at a ratio of 1:1 using block randomization method. QSJB, SLBZ and placebo were given twice per day for 12 weeks. The primary outcome was the Disease Activity Score-28 with C-reactive protein (DAS28-CRP), assessed both as the between-group difference in DAS28-CRP values and the proportion of patients achieving remission (DAS28-CRP<2.6). The secondary outcomes included the 28-tender joint count (TJC28), 28-swollen joint count (SJC28), morning stiffness time, resting pain, Health Assessment Questionnaire (HAQ) score, Physician's Global Assessment of Disease Activity (PhGADA) score, Patient's Global Assessment of Disease Activity (PtGADA) score, rheumatoid factor (RF), anti-cyclic citrullinated peptide antibody (anti-CCP), erythrocyte sedimentation rate (ESR) and CRP. Safety was monitored during the trial.</p><p><strong>Results: </strong>In total, 60 participants were enrolled, 7 dropped out. Fifty-three patients completed the study, with 30 cases in the QSJB+SLBZ group and 23 cases in the QSJB group. Between-group comparisons of DAS28-CRP value at weeks 4 and 12 were not significant (P=0.702, P=0.520). For remission, the week-12 remission rate was numerically higher in the QSJB+SLBZ group than in the QSJB group, without statistical significance (P=0.745). In the QSJB group, both DAS28-CRP and TJC28 were improved after 12 weeks of treatment (P=0.024, P=0.014, respectively), but RF level was elevated at weeks 4 and 12 (both P=0.021). In the QSJB+SLBZ group, DAS28-CRP, TJC28 and SJC28 were improved after 4 weeks (P=0.002, P=0.029 and P=0.001, respectively), TJC28 and SJC28 also improved after 12 weeks (P=0.018, P=0.004, respectively). However, there was no significant difference in DAS28-CRP, anti-CCP, RF, ESR, CRP, TJC28, PhGADA, PtGADA, HAQ, morning stiffness time or resting pain between the two groups (P>0.05). No significant differences were noted between groups in overall adverse events (AEs) and AE-related discontinuation rates (all P>0.05).</p><p><strong>Conclusions: </strong>QSJB alone achieved beneficial clinical responses with acceptable tolerability in treating RA patients with LDA and dampness pattern, while QSJB+SLBZ relieved joint pain faster and thus could be a better alternative option. (Trial registration No. ChiCTR2100053894).</p>","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"875-883"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148599767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment of Palmoplantar Warts in Children with Weiren Xiaoyou Formula: A Case Report.","authors":"Si-Yu Li, Dong-Jie Guo, Lin-Yan Cheng, Xin Liu, Pei-Yao Wang, Jian-Yong Zhu, Fu-Lun Li","doi":"10.1007/s11655-025-4209-y","DOIUrl":"10.1007/s11655-025-4209-y","url":null,"abstract":"","PeriodicalId":10005,"journal":{"name":"Chinese Journal of Integrative Medicine","volume":" ","pages":"926-929"},"PeriodicalIF":3.1,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}